Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-09
2011-08-09
Kelly, Robert M (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C435S320100, C536S023500
Reexamination Certificate
active
07994151
ABSTRACT:
The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.
REFERENCES:
patent: 5785965 (1998-07-01), Pratt
patent: 5814509 (1998-09-01), Tanabe
patent: 5830879 (1998-11-01), Isner
patent: 6723702 (2004-04-01), Conrad et al.
patent: 6814539 (2004-11-01), Farnsworth et al.
patent: 7276594 (2007-10-01), Mori et al.
patent: 2003/0219380 (2003-11-01), Fong et al.
patent: 19940012 (2001-03-01), None
patent: 727490 (1996-08-01), None
patent: WO 95/30013 (1995-11-01), None
patent: WO 97/14307 (1997-04-01), None
patent: WO 00/02589 (2000-01-01), None
Sato (2001) “Role of ETS Family Transcription Factors in Vascular Development and Angiogenesis”, Cell Structure and Function, 26: 19-24.
Aoki, M., et al., “Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets,”Gene Therapy, vol. 7(5), pp. 417-427 (Mar. 2000).
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” 1990, Science, 247: 1306-10.
Cheng et al., 2000, J. Forms. Med. Assoc., 99(8): 603-11. (Abstract Only Provided).
Deonarain, “Ligand-targeted receptor-mediated vectors for gene delivery,” 1998, Exp. Opin. Ther. Pat., 8(1): 53-69.
Eck, et al., 1996, Goodman & Gilman's The Pharacological Basis of Therapeutics, 9thEd., McGraw-Hill, New York, NY, pp. 77-101.
Gorecki, “Prospects and problems of gene therapy: an update,” 2001, Exp. Opin. Emerging Drugs, 6(2); 187-98.
He, H., et al., “Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin through Flk-1/KDR Activation of c-Src,” 1999, J. Biol. Chem., vol. 274, No. 35, pp. 25130-25135.
Ibukiyama, 1996, Jpn. Heart J., 37(3):385-300. (Abstract Only Provided).
Iwasaka, Chika et al.; “Ets-1 Regulates Angiogenesis by Inducing the Expression of Urokinase-Type Plasminogen Activator and Matrix Metalloproteinase-1 and the Migration of Vascular Endothelial Cells”; 1996,Journal of Cellular Physiology, vol. 169, pp. 522-531.
Jones, M.K., et al., “Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing,” 1999, Nat. Med., vol. 5, No. 12, pp. 1418-1423.
Koike et al., Co-Tranfection of Human Prostacyclin Synthase (PGIS) Gene with Hepacyte Growth2000, Circulation, 102(18 Supp.): 224.
Langer, et al., “Where a pill won't reach,” 2003, Scientific American, 288(4): 50-57.
Liu et al., “Efficacy of combination gene therapy with multiple growth factor cDNAs to enhance skin flap survival in a rat model,” 2005, DNA Cell. Biol., 24(11): 751-57. (Abstract Only Provided).
Rudinger, “Characteristics of the amino acids as components of a peptide hormone sequence,”1976, Peptide Hormones, University Park Press, Baltimore, MD., pp. 1-7.
Sato, Y., “Transcription Factor ETS-1 as a Molecular Target for Angiogenesis Inhibition,”Human Cell, vol. 11(4), pp. 207-214 (Dec. 1998).
Schratzberger, et al., “Therapeutic angiogenesis by gene transfer in critical limb and myocardial ischemia,” 2003, Curr. Pharm. Des., 9: 1041-47.
Tsujii, Masahiko, “COX for Kekkan Shinsei,” Igaku no. Ayumi, Apr. 2000, vol. 193, No. 245-248.
Valter, M., et al., “Expression of the Ets-1 Transcription Factor in Human Astrocytomas is Associated with Fms-like Tyrosine Kinase-1 (Flt-1)/Vascular Endothelial Growth Factor Receptor-1 Synthesis and Neoangiogenesis,”Cancer Research, vol. 59(21), pp. 5608-5614 (Nov. 1, 1999).
Vassali, Giuseppe and David A. Dichek; “Gene therapy for arterial thrombosis”;Cardiovascular Research; 1997; pp. 459-469; vol. 35; Elsevier Science B.V.
Verma et al., “Gene therapy-promises, problems and prospects,” 1997, Nature, 389: 239-42.
Watson, D., et al., “Mammalianets-1andets-2genes encode highly conserved proteins,”Proc. Natl. Acad. Sci. USA, vol. 85(21), pp. 7862-7866 (Nov. 1988).
Xin et al., “Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo,” 2001, Am. J. Pathol., 158(3): 1111-20.
Fujitani, K. et al., “Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol,” 1995, Pharmacol Res. 31(2), 121-125.
Nakamura, et al., “Molecular cloning and expression of human hepatocyte growth factor,” Nov. 23, 1989, Nature, 342(6248): 440-443.
Aoki Motokuni
Koike Hiromi
Morishita Ryuichi
Tanabe Tadashi
Anges MG Inc.
Kelly Robert M
Kilpatrick Townsend & Stockton LLP
LandOfFree
Compositions and methods for angiogenic therapy utilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for angiogenic therapy utilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for angiogenic therapy utilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2620966